A new method for prediction of air pollution based on intelligent computation

Al-Janabi, Samaher; Mohammad, Mustafa; Al-Sultan, Ali Yakoob

doi:10.1007/s00500-019-04495-1

“…And several prediction methods based on arti cial intelligence seems effective, but clouds of data or lots of instruments are needed. (22)(23) For this rare cancer, which was sporadic, big data was not available. So we choose a simple decision model only focused on chemotherapy exposure.…”

Section: Discussionmentioning

confidence: 99%

Risk-adapted treatment reduced chemotherapy exposure for clinical stage 1 pediatric testicular cancer

Ye

¹

,

Chen

²

,

Bian

³

et al. 2020

Preprint

0

View full text Add to dashboard Cite

Background: Different from adult clinical stage I (CS1) testicular cancer, surveillance was recommended for CS1 pediatric testicular cancer. For high-risk children, greater than 50% of them suffered relapse and progress during surveillance and adjuvant chemotherapy was administrated. Risk-adapted treatment might reduce chemotherapy exposure for those children. Methods: The decision model was designed and calculated using TreeAge Pro 2011 software. Clinical utilities such as relapse rates of different groups during surveillance or after chemotherapy were collected from literatures. And a survey to urologist was performed to evaluate the toxicity of the first-line and second-line chemotherapy. Using decision analysis model, chemotherapy exposure between risk-adapted treatment and surveillance were compared based on this series of clinical utilities. One-way and two-way tests were administrated to check the feasibility. Results: In base case decision analysis of CS1 pediatric testicular cancer, risk-adapted treatment preferred lower exposure of chemotherapy than surveillance (average: 0.7965 cycle verse 1.3419 cycles). The sensitivity analysis demonstrated that when relapse rate after primary chemotherapy ≤0.10 and the relapse rate of high-risk group ≥0.40, risk-adapted treatment would expose lower chemotherapy, without association of the proportion of low-risk patients, the relapse rate of low-risk group, relapse rate after salvage chemotherapy and toxicity utility of second-line chemotherapy compared to first-line chemotherapy. Conclusions: Using decision analysis, risk-adapted treatment might decrease chemotherapy exposure for these high-risk patients and precious evaluation after orchiectomy was critical to this process. Further clinical study was needed to validate this statement.

show abstract

“…And several prediction methods based on arti cial intelligence seems effective, but clouds of data or lots of instruments are needed. (22)(23)(24) For this rare cancer, which was sporadic, big data was not available. So we choose a simple decision model only focused on chemotherapy exposure.…”

Section: Discussionmentioning

confidence: 99%

Risk-adapted treatment reduced chemotherapy exposure for clinical stage 1 pediatric testicular cancer

Ye

¹

,

Chen

²

,

Bian

³

et al. 2020

Preprint

0

View full text Add to dashboard Cite

Background: Different from adult clinical stage I (CS1) testicular cancer, surveillance was recommended for CS1 pediatric testicular cancer. For high-risk children, greater than 50% of them suffered relapse and progress during surveillance and adjuvant chemotherapy was administrated. Risk-adapted treatment might reduce chemotherapy exposure for those children. Methods: The decision model was designed and calculated using TreeAge Pro 2011 software. Clinical utilities such as relapse rates of different groups during surveillance or after chemotherapy were collected from literatures. And a survey to urologist was performed to evaluate the toxicity of the first-line and second-line chemotherapy. Using decision analysis model, chemotherapy exposure between risk-adapted treatment and surveillance were compared based on this series of clinical utilities. One-way and two-way tests were administrated to check the feasibility. Results: In base case decision analysis of CS1 pediatric testicular cancer, risk-adapted treatment preferred lower exposure of chemotherapy than surveillance (average: 0.7965 cycle verse 1.3419 cycles). The sensitivity analysis demonstrated that when relapse rate after primary chemotherapy ≤0.10 and the relapse rate of high-risk group ≥0.40, risk-adapted treatment would expose lower chemotherapy, without association of the proportion of low-risk patients, the relapse rate of low-risk group, relapse rate after salvage chemotherapy and toxicity utility of second-line chemotherapy compared to first-line chemotherapy. Conclusions: Using decision analysis, risk-adapted treatment might decrease chemotherapy exposure for these high-risk patients and precious evaluation after orchiectomy was critical to this process. Further clinical study was needed to validate this statement.

show abstract

“…Several prediction methods based on arti cial intelligence have been developed, but clouds of data or lots of instruments are needed. (22)(23)(24) For this rare cancer, which is sporadic, big data are not available. Therefore, we chose a simple decision model focused on chemotherapy exposure.…”

Section: Discussionmentioning

confidence: 99%

Risk-adapted treatment reduced chemotherapy exposure for clinical stage 1 pediatric testicular cancer

Ye

¹

,

Chen

²

,

Bian

³

et al. 2020

Preprint

0

View full text Add to dashboard Cite

Background: Different from adult clinical stage I (CS1) testicular cancer, surveillance has been recommended for CS1 pediatric testicular cancer. However, among high-risk children, more than 50% suffer a relapse and progression during surveillance, and adjuvant chemotherapy needs to be administered. Risk-adapted treatment might reduce chemotherapy exposure among these children.Methods: A decision model was designed and calculated using TreeAge Pro 2011 software. Clinical utilities such as the relapse rates of different groups during surveillance or after chemotherapy were collected from the literature. A survey of urologists was conducted to evaluate the toxicity of first-line and second-line chemotherapy. Using the decision analysis model, chemotherapy exposure of the risk-adapted treatment and surveillance strategies were compared based on this series of clinical utilities. One-way and two-way tests were applied to check the feasibility.Results: In the base case decision analysis of CS1 pediatric testicular cancer, risk-adapted treatment resulted in a lower exposure to chemotherapy than surveillance (average: 0.7965 cycles verse 1.3419 cycles). The sensitivity analysis demonstrated that when the relapse rate after primary chemotherapy was ≤0.10 and the relapse rate of the high-risk group was ≥0.40, risk-adapted treatment would result in a lower exposure to chemotherapy, without any association with the proportion of low-risk patients, the relapse rate of the low-risk group, the relapse rate after salvage chemotherapy or the toxicity utility of second-line chemotherapy compared to first-line chemotherapy.Conclusions: Based on the decision analysis, risk-adapted treatment might decrease chemotherapy exposure for these high-risk patients, and an evaluation after orchiectomy was critical to this process. Additional clinical studies are needed to validate this statement.

show abstract

A new method for prediction of air pollution based on intelligent computation

Cited by 158 publications

References 27 publications

Risk-adapted treatment reduced chemotherapy exposure for clinical stage 1 pediatric testicular cancer

Risk-adapted treatment reduced chemotherapy exposure for clinical stage 1 pediatric testicular cancer

Risk-adapted treatment reduced chemotherapy exposure for clinical stage 1 pediatric testicular cancer

Risk-adapted treatment reduced chemotherapy exposure for clinical stage 1 pediatric testicular cancer

Contact Info

Product

Resources

About